Pyxis Oncology Q2 net loss $25.3M; $50M private placement extends cash runway into Q2 2027

Pyxis Oncology, Inc.

2026-Q2 EPS reported -$0.76

Net loss $25.3M ($0.40/share) vs $18.4M ($0.30) in Q2 2025; R&D $16.1M, G&A $9.9M.
Completed July 2, 2026 private placement: ~$50M upfront gross, up to $64M more if warrants exercised.
Cash, equivalents, restricted cash, and short-term investments $34.5M at June 30, 2026; runway into Q2 2027.
MICVO Phase 1 monotherapy update in 2L+ R/M HNSCC expected Fall 2026; pembrolizumab combo update Q4 2026.
Interim CEO Tom Civik cites financing and clinical execution; shares outstanding 83.4M as of Aug 12, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.